Apimeds Pharmaceuticals
Matawan
About Apimeds Pharmaceuticals
Apimeds Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on developing Apitox, an intradermally administered, purified bee venom-based biologic licensed from Apimeds Korea. Apitox is being evaluated as a potential treatment for knee osteoarthritis in patients unresponsive to conventional therapies. Apimeds Pharmaceuticals is also exploring Apitox's application in managing symptoms of multiple sclerosis.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Total funding: $100.0M
- Funding stage: IPO
- Last round: Post-IPO Equity (Dec 2025)
- Ticker: nysemkt:APUS
- Website: apimedsus.com
- Phone: +1 808-209-7887
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/apimeds-pharmaceuticals-4484 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.